John Mendlein leaves Moderna for Flagship; Paul Sekhri to steer first xenotransplantation trials as eGenesis CEO
→ John Mendlein is out at Moderna just a year — a momentous year, no less, that saw Moderna reap a $604 million IPO — after becoming president of the biotech unicorn. The new role as executive partner at Flagship Pioneering brings him back to his “roots and passion for creating and growing innovative platform companies,” he said in a statement. He will have stay another six months as a consultant to Moderna, where he led a cross-functional team prepping the company for the public market as well as corporate strategy, partnering, legal and intellectual property.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.